Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-018-4225-7
Abstract: Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for… read more here.
Keywords: therapy; dota substance; dota; targeted alpha ... See more keywords
Locoregional Treatment of Glioblastoma With Targeted α Therapy
Sign Up to like & getrecommendations! Published in 2023 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004608
Abstract: Background Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [213Bi]Bi-DOTA–substance P (SP)… read more here.
Keywords: dota 225ac; dota; 225ac dota; 213bi dota ... See more keywords
In Vivo evaluation of newly synthesized 213Bi-conjugated alpha-melanocyte stimulating hormone (α-MSH) peptide analogues in melanocortin-1 receptor (MC1-R) positive experimental melanoma model.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of pharmaceutical and biomedical analysis"
DOI: 10.2139/ssrn.4369312
Abstract: Given the rising pervasiveness of melanocortin-1 receptor (MC1-R) positive melanoma malignum (MM) and pertinent metastases, radiolabelled receptor-affine alpha-melanocyte stimulating hormone-analogue (α-MSH analogue) imaging probes would be of crucial importance in timely tumor diagnostic assessment. Herein… read more here.
Keywords: mc1; receptor mc1; dota; 213bi dota ... See more keywords